A recent report describes a unique, high-value application of ultra-widefield (UWF™) retinal imaging in the treatment of Diabetic Macular Edema, or DME.
There are over 400 million people1 worldwide afflicted with diabetes and the long-term incidence of DME in this population is estimated at twenty to forty percent2. UWF imaging is already impacting the diagnosis and treatment of DME as well as Diabetic Retinopathy (DR), which frequently precedes or is associated with DME. Ultra-widefield imaging is unique in that it visualizes a much larger area of the retina (200°, or over 80%) as compared to conventional techniques that may image 45° or less of the retina. By imaging the peripheral retina practitioners and researchers have shown they can more accurately measure the extent of diabetic retinopathy3 as well as better predict the risk of future progression4. UWF is also helping public health initiatives by enabling accurate and cost-effective screening for DR5.
This novel application of UWF imaging supports a relatively new therapy for DME. While the standards for DME treatment are undergoing intense study6, corticosteroids are often prescribed if anti-VEGF medications fail to control the chronic inflammation associated with DME. These corticosteroids are administered by direct injection into the eye, a …